E-Z-EM: Angiodynamics Japan Distribution

NEWS RELEASE


FOR IMMEDIATE RELEASE
February 2, 1998			
For more information please contact:
Michael P. Cody
Director, Corporate Communications
(518) 798-1215 Ext. 140

ANGIODYNAMICS SIGNS EXCLUSIVE JAPANESE DISTRIBUTION AGREEMENT

Queensbury, NY, February 2, 1998.  AngioDynamics, Inc. a wholly owned
subsidiary of E-Z-EM, Inc. (Amex:  EZM.A and EZM.B) has announced it has
entered into an exclusive five year agreement with Eiken Kizai Co., Ltd. for
distribution of AngioDynamics peripheral vascular products in Japan.

Eiken Kizai is a Tokyo based manufacturer and distributor of medical devices
and is an Eiken Group Company.  The Eiken Group is a large, well established
and respected manufacturer of iodinated compounds for X-ray diagnosis and
contrast media for MRI diagnosis.  Eiken Kizai has formed a separate
business unit to focus on the distribution of endovascular products.

Eamonn P. Hobbs, AngioDynamics president and ceo said:  "The agreement with
Eiken Kizai is a commitment for both companies to continue expanding our
business in Japan.  AngioDynamics is serious about our business in Japan and
we have invested considerable resources to meet the specific needs of our
Japanese customers."  

Michael Dellario, AngioDynamics director, business development said:  "Eiken
Kizai has done a good job of developing the renal dialysis market.  We
believe Japan has the world's largest population of patients, estimated to
be more than 150,000, with end-stage renal disease.  Our Pulse*Spray
Infusion system is proving to be effective in maintaining dialysis access in
this patient group.  The recent FDA clearance of our Pulse*Spray Injector
should expedite the registration process in Japan.  This injector is
anticipated to be used for dialysis access maintenance and drug delivery
into the liver.  We intend to offer more products to treat these end-stage
renal dialysis patients.

The distribution of medical products in Japan is very complex and involves
multiple layers of sub-distributors.  Eiken Kizai acting as both our
importer and exclusive distributor will allow us to conduct more effective
training, improve communications and expedite the product registration
process."

Takashi Sato, Eiken Kizai president said:  "I am very happy that Eiken Kizai
Co., Ltd. has established a contractual agreement in the field of
endovascular products with AngioDynamics, Inc. a company with great
technical strengths.

Based on this firm partnership with AngioDynamics, Eiken Kizai aims to
further improve our organization and sales capacity, while pursuing business
development in the vascular field.  In Japan, especially, the IVR market is
expanding, and I believe that we will be fully able to meet the expectations
held by AngioDynamics." 

The statements made in this press release contain certain forward-looking
statements that involve a number of risks and uncertainties.  Actual events
or results may differ from the company's expectations.  In addition to
matters described in this release, future actions by the FDA, results of
pending or future clinical trials, as well as the risk factors listed from
time to time in the SEC filings of E-Z-EM, Inc. including but not limited to
its Form 10-Q for the quarter ended November 29, 1997, as well as its
Annual Report on Form 10-K, may affect the actual results achieved by the
Company.

                                  # # #

End